Scleroderma Completed Phase Trials for Ambrisentan (DB06403)

Also known as: Dermatosclerosis

IndicationStatusPhase
DBCOND0013449 (Scleroderma)CompletedNot Available
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01093885Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic SclerosisTreatment